Founder, CEO, and Board Member: Lao Saal, MD PhD
A childhood cancer survivor himself, Lao is passionate about improving cancer diagnosis and treatment. Lao trained at Columbia University College of Physicians and Surgeons in New York City, where he received MD and PhD degrees, with distinction, in 2008. After clinical postdoctoral research at the Memorial Sloan Kettering Cancer Center, Lao established an independent research group at Lund University, Sweden in 2009. Since then, as Associate Professor and Head of the Translational Oncogenomics Unit, he has led a team spearheading research in circulating tumor DNA, mutational analyses of cancer, and RNA-sequencing. This research forms the basis of SAGA Diagnostics. He is an author of over 40 publications in leading journals such as Nature Genetics, Science, and PNAS.
Director of Corporate and Business Development: Åke Nilsson
Åke is a seasoned businessman with over 30 years experience in leadership and management roles at small and large life science companies such as Astra (now AstraZeneca), Apoteket, and Melacure Therapeutics, focusing on strategic business development, in- and out-licensing, M & A, and international marketing. He is serves as Director of Corporate and Business Development.
Co-Founder, CTO, and Board Member: Anthony George, MSc
Anthony graduated cum laude with a BSc in computer science and engineering from the University of Toledo, Ohio, in 2005 and performed Masters studies in molecular biology and genetics at Lund University on “Targeted High-Throughput Deep-Sequencing of Cancer Associated Genes and SNP Array Analysis of Human Breast Cancer”. He is co-inventor of the IBSAFE technology and serves as Chief Technical Officer of SAGA Diagnostics.
Manager, Clinical Laboratory and Quality Assurance: Karolina Holm, PhD
Karolina graduated in 2011 with a PhD in experimental oncology from Lund University, Sweden, studying the genetic and epigenetic characterization of breast cancer. She has over 6 years of clinical diagnostics laboratory experience, performing NGS mutational analyses for lung carcinoma and malignant melanoma, as well as screening for BRCA1/2 hereditary cancer mutations. Today she is Manager of SAGA’s Clinical Laboratory and Quality Assurance.
BOARD OF DIRECTORS
Chairman of the Board: Greg Batcheller, JD, LLM
Greg brings a strong track record from his previous positions in the life science industry as a executive decision maker, company founder, and commercial lawyer. He was CEO of DuoCort, is a Partner at P.U.L.S., and co-founded Laccure. He is currently involved with a number of companies including NeuroVive, Xintela, and Monocl Software. Greg is an accomplished dealmaker and has successfully negotiated many international licensing and M&A deals in Europe, the U.S., and China.
Business Development and Board Member: Johanna Asklin, PhD
Johanna earned her PhD in immunology and microbiology from Gothenburg University in 2006. She has over 7 years experience in commercial project management and business development, beginning at Intercell AG (now Valneva) in vaccine development and later at the Danish Statens Serum Institut from 2008-2014. She is Innovation Manager at LU Innovation with a focus on the commercialization of cancer research.
Board Member: Henrik Winther, PhD
Henrik has been at the forefront of companion diagnostics for over 10 years. From 2006, he was R&D Director at Dako A/S and spearheaded the development the FDA-approved HercepTest CDx breast cancer assay, and was a dealmaker in the acquisition by Agilent Technologies in 2012. From 2013-2017, he continued at Agilent in Santa Barbara, CA, as VP and GM of the Companion Diagnostics Division, and in addition to scaling up the division 5x, he increased revenues by 45% each year.
Deputy Board Member: Christine Widstrand, PhD
Christine has over 15 years of experience of research and development and holds a PhD in Analytical Chemistry. She has been the co-founder of several companies in the life science field, including founding and serving as CEO of MIP Technologies (2000-2009), and has been a board member of a dozen start-ups. Today, Christine is the Executive Vice President at LU Holding AB and has the overall responsibility for the development of their 40 portfolio companies.
SCIENTIFIC ADVISORY BOARD
Scientific Advisor: Anne-Lise Borresen-Dale, PhD
Anne-Lise is world-renown cancer researcher, emeritus Head of the Department of Genetics at the Norwegian Radium Hospital in Oslo, Norway, and former President of the European Association for Cancer Research. She is true a pioneer in the field of cancer genomics and application of high-throughput methods and has authored over 400 publications and won numerous awards including the 2015 Distinguished Lectureship in Breast Cancer from the American Association for Cancer Research.
Scientific Advisor: Niklas Loman, MD PhD
Niklas is a highly experienced Clinical Oncologist and Senior Attending Physician at the Department of Oncology, Skåne University Hospital, and served as Head of Section for Breast Cancer, CNS, and Melanoma, and Clinical Head of Diagnosis for Breast Cancer for Region Skåne (1,100 new diagnoses/year). He earned his PhD in 2003 from Lund University and has published over 50 articles on cancer genetics, with major contributions in the area of hereditary cancer and clinical trials.